A Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231, Encoding for a Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m), in Healthy Adults
ModernaTX, Inc. is advancing mRNA-6231, an innovative therapeutic candidate targeting the immune modulation space through a novel fusion protein approach. The Phase 1 trial, which has been completed, aims to establish safety and tolerability profiles for escalating doses of mRNA-6231 in healthy adults. Given the growing interest in mRNA-based therapies, particularly in oncology and autoimmune diseases, successful outcomes could position Moderna favorably against competitors in the immunotherapy landscape. The trial's completion and subsequent data analysis will be critical for informing potential partnerships or further development strategies, especially in light of the increasing demand for effective immunomodulatory agents.
Indication: Healthy Volunteers
Modality: RNA therapy
Target: Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m)
Sponsor: ModernaTX, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m)
View original source fields
Condition raw: Healthy Volunteers
Condition normalized: Healthy Volunteers
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m)
Target normalized: Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m)